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F A C U L T Y   O F   S C I E N C E  
U N I V E R S I T Y   O F   C O P E N H A G E N 
Ethical work and Human Gene Therapy 
Courtney Addison 
 
1972   Recombinant DNA  
 technology first appears1 
 
1974   Berg letter to Science, 
 moratorium on several 
 kinds of rDNA research2 
 
1976  ‘Asilomar 2’: guidelines
 made for rDNA research, 
 moratorium lifted3 
 
1980  Illicit human gene therapy
 protocol performed by 
 Martin Cline, UPenn4 
 
1982  President’s Commission 
 on gen. engineering  
 publishes Splicing Life6 
 
1989  First human gene transfer 
 experiment (cell marking)7 
 
1990  First human gene therapy 
 begins for ADA-SCID8 
 
Mid-90s  Slow progress noted, 
 critiques of rush to clinic 
 
1999  Patient dies in UPenn trial. 
 Many trials globally halted for 
 assessment. 
 
2002  Two patients in French trial 
 get leukemia, one dies.  
 
2003  First gene therapy gains 
 market approval in China 
 
2012  First Euro gene therapy, 
 Glybera, approved 
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This poster sets out to explore the types of ethical work that have gone into Human Gene Therapy. Drawing inspiration from the recent ethical turn in anthropology, it seeks to open up 
questions of ethics and move beyond the idea of the ethical as synonymous with standardised guidelines. This fits into an ongoing endeavour to understand how human gene therapy, as  
a highly experimental medico-scientific field, was originally established and subsequently sustained, despite several high profile patient deaths and almost a decade of slow progress. I 
point to three different types of ethical work that enabled the field’s continuation: ethical boundary work; the use of existing bioethical standards; and an underlying ethical imperative.  
 
THE ETHICAL 
 IMPERATIVE 
The ethical imperative makes it unthinkable for gene therapy, once technically possible, to be denied from those living with severe and otherwise  
incurable diseases. It enables safety concerns to be overridden by the ultimate ethos that suffering is untenable if a means to end it exists. This  
imperative has acted as an ethical engine, sustaining the field’s momentum in the face of high profile patient deaths and periods of slow success. 
HUMAN GENE THERAPY 
HGT grew out of advances in microbiology (esp. 
recombinant DNA) in the late 1900s, and became  
a reality in 1990, when the first trial began on two  
children with a severe immune condition. The field  
met much hype and a surge of investment in the  
1990s, but tangible successes (i.e. safe and effective  
therapies) proved slow to come. The new millennium  
saw 2 patient deaths in unrelated French and American  
trials, ostensibly shaking the field. Progress gradually  
became evident as the 2000s got underway, and today  
three gene therapy products have reached the market. 
1800 
CLINICAL 
HGT TRIALS 
COMPLETE 
OR ONGOING 
    ANTHROPOLOGY 
     & ETHICS 
Anthropologists10,11,12 have shown that  
while ethical standards (e.g. informed  
consent, risk-benefit analysis) make ethics operable,  
they do not encompass ethical practice. Rather, ethics are embedded in the ongoing  
everyday work of striving to be a good (or good enough) person amongst others;  
they manifest as forms of future-making amidst conditions of present uncertainty. 
 
ETHICAL 
BOUNDS 
   In the early stages of human gene therapy, concerns  
   were voiced about the safety and viability of the  
   potential field. A key strategy that enabled the field to 
get underway was the ethical boundary work done (primarily by scientific 
actors) to demarcate acceptable from unacceptable gene therapy.  
 
W. French Anderson made two demarcations, which marked out a space for 
an ethically acceptable field of gene therapy. These were: somatic vs. germ 
line gene therapy, and gene therapy for purposes of therapy vs. enhancement.  
Somatic gene therapy is 
carried out on somatic cells, 
meaning changes are not  
passed to patients’ children. 
 
 
 
 
Therapeutic gene therapy 
aims to ameliorate disease,  
rather than accentuate 
 certain characteristics.  
Boundary work (Gieryn 19919) denotes the discursive delineation of scientific 
spaces. It is credibility-granting work, consolidating the epistemic authority  
of a given scientific practice through the ongoing work of refiguring its edges. 
1 
BIOETHICAL  
STANDARDS 
       Human gene therapy is governed by many of  
       the same ethical standards as other experimental 
       medico-scientific work. Many of these are derived 
from the Declaration of Helsinki, and enforced by a host of regulatory bodies. 
Standard ethical practice involves formalised risk-benefit analyses of a trial, full 
informed consent for participants, plus regular monitoring and reporting. 
 
Implementing standards of this sort made the field of gene therapy governable by 
the assigned regulators. They have not, however, proven infallible. In the 1999 
death of Jesse Gelsinger, for example, numerous issues were revealed including 
failure to report animal deaths and investigators conflicts of interest. Such failings 
occur in other fields, but appear here in a context of high scrutiny and concern.   
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